IONS
Price:
$36.08
Market Cap:
$5.70B
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with ...[Read more]
Industry
Biotechnology
IPO Date
1991-05-17
Stock Exchange
NASDAQ
Ticker
IONS
According to Ionis Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 6.81B. This represents a change of -14.83% compared to the average of 7.99B of the last 4 quarters.
The mean historical Enterprise Value of Ionis Pharmaceuticals, Inc. over the last ten years is 6.07B. The current 6.81B Enterprise Value has changed 11.12% with respect to the historical average. Over the past ten years (40 quarters), IONS's Enterprise Value was at its highest in in the March 2019 quarter at 11.53B. The Enterprise Value was at its lowest in in the June 2016 quarter at 3.17B.
Average
6.07B
Median
6.21B
Minimum
3.34B
Maximum
8.30B
Discovering the peaks and valleys of Ionis Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 77.44%
Maximum Annual Enterprise Value = 8.30B
Minimum Annual Increase = -50.56%
Minimum Annual Enterprise Value = 3.34B
Year | Enterprise Value | Change |
---|---|---|
2023 | 8.30B | 75.97% |
2022 | 4.72B | 41.30% |
2021 | 3.34B | -50.56% |
2020 | 6.75B | 1.25% |
2019 | 6.67B | 18.27% |
2018 | 5.64B | -1.93% |
2017 | 5.75B | 2.41% |
2016 | 5.61B | -19.88% |
2015 | 7.01B | 1.35% |
2014 | 6.91B | 77.44% |
The current Enterprise Value of Ionis Pharmaceuticals, Inc. (IONS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
5.45B
5-year avg
5.95B
10-year avg
6.07B
Ionis Pharmaceuticals, Inc.’s Enterprise Value is less than Arrowhead Pharmaceuticals, Inc. (0), greater than BioMarin Pharmaceutical Inc. (2.87B), less than Incyte Corporation (12.56B), less than Apellis Pharmaceuticals, Inc. (12.19B), greater than Viking Therapeutics, Inc. (4.20B), greater than Intercept Pharmaceuticals, Inc. (4.67B), greater than Terns Pharmaceuticals, Inc. (915.81M), greater than Akero Therapeutics, Inc. (234.86M), greater than Reata Pharmaceuticals, Inc. (1.70B), greater than Seagen Inc. (6.64B), less than Alnylam Pharmaceuticals, Inc. (42.84B), less than Exelixis, Inc. (31.45B), less than Halozyme Therapeutics, Inc. (9.50B), less than PTC Therapeutics, Inc. (7.35B), greater than Krystal Biotech, Inc. (3.39B), greater than Sarepta Therapeutics, Inc. (4.25B), less than Iovance Biotherapeutics, Inc. (12.73B), greater than Madrigal Pharmaceuticals, Inc. (2.19B), greater than null (6.67B),
Company | Enterprise Value | Market cap |
---|---|---|
0 | $2.46B | |
2.87B | $12.63B | |
12.56B | $13.45B | |
12.19B | $4.13B | |
4.20B | $4.72B | |
4.67B | $794.69M | |
915.81M | $503.69M | |
234.86M | $1.98B | |
1.70B | $6.57B | |
6.64B | $43.15B | |
42.84B | $31.25B | |
31.45B | $9.56B | |
9.50B | $6.00B | |
7.35B | $3.51B | |
3.39B | $4.63B | |
4.25B | $11.53B | |
12.73B | $2.27B | |
2.19B | $6.78B | |
6.67B | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ionis Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Ionis Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Ionis Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Ionis Pharmaceuticals, Inc. (IONS)?
What is the 3-year average Enterprise Value for Ionis Pharmaceuticals, Inc. (IONS)?
What is the 5-year average Enterprise Value for Ionis Pharmaceuticals, Inc. (IONS)?
How does the current Enterprise Value for Ionis Pharmaceuticals, Inc. (IONS) compare to its historical average?